Antisense Therapeutics Limited (AU:PER) has released an update.
Percheron Therapeutics has successfully completed a crucial nine-month toxicology study on non-human primates for its leading drug candidate, avicursen, with consistent and reversible findings, paving the way for FDA discussions and potential future U.S. clinical trials. The completion aligns with the regulatory requirements for avicursen, which targets rare diseases such as Duchenne Muscular Dystrophy, and is also undergoing a phase IIb clinical trial with results expected by December 2024.
For further insights into AU:PER stock, check out TipRanks’ Stock Analysis page.
